VHIO Scientific Manager is a pioneer in translational research
en_news
Queen Sofía and Councillor Marina Geli assist at the opening ceremony
This research studied the action mechanisms of two drugs—lapatinib and trastuzumab—in combination for the treatment of HER2-positive breast cancer. Lapatinib is a molecule which, when combined with trastuzumab, neutralizes the activity of the HER2 receptor and improves the effect of the antibody
